Identification of HBV DNA sequences that are predictive of response to lamivudine therapy

Numerous studies have shown that resistance to long‐term lamivudine therapy occurs in as many as ⅔ of hepatitis B virus (HBV) chronic carriers. Additional studies have shown that reversion of HBV mutations in the precore/core promoter region conferring an HBeAg‐negative phenotype/genotype can occur in up to 30% of lamivudine‐treated patients. In this study, sequences of the HBV polymerase and precore/core coding regions in 26 HBV‐infected patients (24 with HBeAg‐negative virus infection, 25 genotype D, 1 genotype A) treated for 27 to 53 months with lamivudine were analyzed to determine the relationship between pretreatment HBV DNA sequence patterns and long‐term treatment response, and the effect of therapy on the status of HBV precore mutations. Reversions of precore mutations A1762T/G1764A and G1896A were observed in 29% and 25% of patients, respectively, but none became HBeAg‐positive. These data are consistent with previously published reversion frequencies for 2 other groups of lamivudine‐treated patients. Two naturally‐occurring DNA polymorphisms at aa91 and aa256 of the HBV polymerase were observed in the pretreatment serum samples, which correlated with extended treatment failure. In conclusion, reversion of mutations conferring an HBeAg‐negative phenotype occur relatively frequently under lamivudine therapy. Furthermore, at least in HBeAg‐negative patients infected predominately with HBV genotype D, specific viral DNA sequences which are present before therapy appear to be useful as predictors of long‐term response to lamivudine treatment. (HEPATOLOGY 2004;39:64–73.)

[1]  Fabien Zoulim,et al.  Monitoring Drug Resistance in Chronic Hepatitis B Virus (HBV)-Infected Patients during Lamivudine Therapy: Evaluation of Performance of INNO-LiPA HBV DR Assay , 2002, Journal of Clinical Microbiology.

[2]  C. Tong,et al.  Two distinct types of hepatitis B virus core promoter variants in Yemeni blood donors , 2002, Journal of medical virology.

[3]  D. Vassilopoulos,et al.  Hepatitis B e antigen–negative chronic hepatitis B , 2001, Hepatology.

[4]  S. Hadziyannis,et al.  Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B , 2000, Hepatology.

[5]  E. Schiff,et al.  Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B , 2002, Hepatology.

[6]  M. Manns,et al.  Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene. , 2002, Virology.

[7]  S. Sarafianos,et al.  Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC) , 2001, Journal of Virology.

[8]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. , 1998, Hepatology.

[9]  Y. Cheng,et al.  Role of additional mutations outside the YMDD motif of hepatitis B virus polymerase in L(-)SddC (3TC) resistance. , 1998, Biochemical pharmacology.

[10]  M. Rizzetto,et al.  Response of pre‐core mutant chronic hepatitis B infection to lamivudine , 2000, Journal of medical virology.

[11]  A. Lok,et al.  Management of hepatitis B: 2000--summary of a workshop. , 2001, Gastroenterology.

[12]  H. Zhuang,et al.  Core promoter mutations (A1762T and G1764A) and viral genotype in chronic hepatitis B and hepatocellular carcinoma in Guangxi, China , 2002, Journal of medical virology.

[13]  D. Richman,et al.  Nomenclature for antiviral‐resistant human hepatitis B virus mutations in the polymerase region , 2001, Hepatology.

[14]  R. Purcell,et al.  Type D hepatitis: The clinical significance of hepatitis D virus RNA in serum as detected by a hybridization‐based assay , 1986, Hepatology.

[15]  D. Pillay,et al.  Mutations in the hepatitis B virus DNA polymerase associated with antiviral resistance , 1998 .

[16]  A. Couroucé,et al.  Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. , 1994, Virology.

[17]  J. Gerin,et al.  Hepatitis B virus DNA in the sera of HBsAg carriers: A marker of active hepatitis B virus replication in the liver , 1981, Hepatology.

[18]  D. Vassilopoulos,et al.  Treatment of HBeAg-negative chronic hepatitis B. , 2003, Seminars in liver disease.

[19]  K. Reddy,et al.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation , 1997, The Lancet.

[20]  L. Stuyver,et al.  Line Probe Assay for Monitoring Drug Resistance in Hepatitis B Virus-Infected Patients during Antiviral Therapy , 2000, Journal of Clinical Microbiology.

[21]  M. Brunetto,et al.  Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. , 2003, Journal of hepatology.

[22]  L. Stuyver,et al.  Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B , 2000, Hepatology.

[23]  L. Stuyver,et al.  Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity. , 2000, Journal of hepatology.

[24]  U. Akarca,et al.  Mutations in the pre-core region of hepatitis B virus serve to enhance the stability of the secondary structure of the pre-genome encapsidation signal. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[25]  C. Chu,et al.  Clearance of the original hepatitis B virus YMDD‐motif mutants with emergence of distinct lamivudine‐resistant mutants during prolonged lamivudine therapy , 2000, Hepatology.

[26]  S. Hadziyannis,et al.  Course of virologic breakthroughs under long‐term lamivudine in HBeAg‐negative precore mutant HBV liver disease , 2002, Hepatology.

[27]  Ding‐Shinn Chen,et al.  Sequence analysis of pre‐S/surface and pre‐core/core promoter genes of hepatitis B virus in chronic hepatitis C patients with occult HBV infection , 2002, Journal of medical virology.

[28]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[29]  Y. Chrétien,et al.  HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. , 2000, Transplantation.

[30]  M. Yuen,et al.  Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy , 2001, Hepatology.

[31]  J. Dienstag,et al.  Quantitation of hepatitis B viremia and emergence of YMDD variants in patients with chronic hepatitis B treated with lamivudine. , 1999, The Journal of infectious diseases.

[32]  K. Chayama,et al.  Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy , 1998, Hepatology.

[33]  A. Lok,et al.  Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy , 2000, Hepatology.

[34]  K. Hahm,et al.  Reversion from precore/core promoter mutants to wild‐type hepatitis B virus during the course of lamivudine therapy , 2000, Hepatology.

[35]  K. Walters,et al.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine , 1998 .